SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
Condition: Early Parkinson's Disease Interventions: Drug: PT320 2.0mg Placebo; Drug: PT320 2.0 mg; Drug: PT320 2.5 mg Sponsor: Peptron, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials